Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission
Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
- You are here:
- Home »
- Blog »
- Multiple Myeloma »
- CAR-T Adverse Events
CAR-T Adverse Events
CAR-T therapy holds a great deal of potential for multiple myeloma patients and survivors. I read about a growing number of MM patients undergoing CAR-T therapy almost daily. According to the research linked below, everyone undergoing CAR-T therapy develops serious adverse events aka side effects.
For the first time ever, a client told me that he was newly diagnosed and seriously considering CAR-T therapy for his first line of therapy. I thought I should study up on the pros and cons of CAR-T therapy for MM.
I am a long-term MM survivor. Induction, consolidation, and an ASCT taught me that conventional oncology may not talk about or explain adverse events aka side effects.
I say this because I live with many serious long-term side effects. All from FDA approved “safe and effective” chemotherapy and radiation.
Don’t misunderstand me. The MM patient who has relapsed 3,4 maybe even 5 times, who has run out of therapy options may undergo CAR-T therapy. I understand this. I’m simply explaining CAR-T adverse events.
What are the risks and benefits of CAR-T Therapy?
Are you a MM survivor who is considering CAR-T therapy? If you’d like to learn more about evidence-based non-conventional therapies let me know- David.PeopleBeatingCancer@gmail.com
Hang in there,
David Emerson
- MM Survivor
- MM Cancer Coach
- Director PeopleBeatingCancer
Incidence of Secondary T-Cell Malignancies Following CAR T-Cell Therapy
“Investigators have found that second primary malignancies following chimeric antigen receptor (CAR) T-cell therapy were reported in 4.3% of CAR T-cell therapy adverse event reports submitted to the U.S. Food and Drug Administration’s (FDA) Adverse Event Reporting System…
Conclusions
Although the investigators uncovered second primary malignancies in the FDA’s Adverse Event Reporting System, they were unable to establish causation based on the data provided by the agency. According to the American Cancer Society, patients undergoing cancer treatment may face an elevated risk of developing secondary malignancies as a result of several common treatments, including chemotherapy and radiation.
“Patients receiving CAR T-cell therapy are often heavily pretreated with other drugs, which can also contribute to the development of secondary [malignancies],” explained Marcela Maus, MD, PhD, an attending physician at Massachusetts General Hospital. “At this point, the risk of secondary [malignancies] after CAR T-cell therapy cannot be definitively attributed to the CAR T cells, [since] all of these patients received multiple prior chemotherapy agents that are known to elevate the risk of secondary [malignancies],” she underscored.
The investigators indicated that because the Adverse Event Reporting System relies on voluntary reporting of adverse events, duplicate submissions from providers, patients, and manufacturers may have occurred. Additionally, the lack of data on the total number of CAR T-cell therapies prescribed may have made it challenging to estimate the incidence of adverse events such as second primary malignancies across all CAR T-cell therapy use.
CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges
“A meta-analysis of the KarMMa and LEGEND-2 trials revealed up to 80% of patients experience CRS, with 14.1% experiencing grade 3 toxicities or higher with a median duration of 7 days for bb2121 and 9 days for LCAR-B38M.34 The rates and severity of CRS correlate with the dose of infused CAR T-cells.14…”
Current concepts in the diagnosis and management of cytokine release syndrome
“Potentially life-threatening complications of CRS include cardiac dysfunction, adult respiratory distress syndrome, neurologic toxicity, renal and/or hepatic failure, and disseminated intravascular coagulation…